吸烟者肺过度充气与冠状动脉疾病的关联
本研究分析匹兹堡大学COPD SCCOR队列(n=481)和COPDGene队列(n=2,580)中吸烟量>10包年的现吸烟者和既往吸烟者,分别用体积描记法和吸呼气CT肺容积评估肺过度充气,以冠状动脉钙化评分评估亚临床冠状动脉疾病,以自我报告的冠状动脉疾病或心肌梗死史定义临床冠状动脉疾病。多因素模型调整肺表型和冠状动脉疾病危险因素后,肺过度充气是唯一与钙化评分(每呼气/吸气CT肺容积高0.2:OR 1.2,95%CI 1.1-1.5,P=0.02)、临床冠状动脉疾病(OR 1.6,95%CI 1.1-2.3,P=0.01)和心肌梗死(COPDGene中OR 1.7,95%CI 1.0-2.8,P=0.05)相关的表型。FEV1和肺气肿在仅调整冠状动脉疾病危险因素时与冠状动脉疾病风险增加相关(P<0.05),但调整肺过度充气后关联减弱。在气流阻塞者中结果相同,且两个队列均存在该关联。
要点
- 在吸烟者中,调整肺表型和冠状动脉疾病危险因素后,肺过度充气是唯一与冠状动脉钙化评分(OR 1.2,95%CI 1.1-1.5,P=0.02)、临床冠状动脉疾病(OR 1.6,95%CI 1.1-2.3,P=0.01)和心肌梗死(OR 1.7,95%CI 1.0-2.8,P=0.05)独立相关的肺表型。
- FEV1和肺气肿在仅调整冠状动脉疾病危险因素时与冠状动脉疾病风险增加相关(P<0.05),但调整肺过度充气后关联减弱。
- 在气流阻塞(FEV1/FVC<0.70)的吸烟者中结果相同,且肺过度充气与冠状动脉疾病的关联在两个队列中均存在。
- 肺过度充气与临床和亚临床冠状动脉疾病强相关,后续研究应考虑测量肺过度充气并探讨其在吸烟者冠状动脉疾病中的机制作用。
适用人群与场景
- 匹兹堡大学COPD SCCOR队列(n=481)和COPDGene队列(n=2,580)中吸烟量>10包年的现吸烟者和既往吸烟者。
- 分析在所有吸烟者中进行,并在气流阻塞(FEV1/FVC<0.70)者中重复。
诊断标准与关键阈值
- 气流阻塞定义为FEV1与FVC比值<0.70。
- 亚临床冠状动脉疾病用冠状动脉钙化评分评估;临床冠状动脉疾病定义为自我报告的冠状动脉疾病史或心肌梗死史。
研究设计与关键结果
- 研究类型为两个队列(SCCOR队列n=481和COPDGene队列n=2,580)的分析,因方法学差异分别分析。
- 肺表型(气流受限、肺气肿、肺过度充气、弥散功能和气道重塑影像学指标)彼此呈弱至中度相关(r<0.7)。
- 多因素模型调整肺表型和冠状动脉疾病危险因素后,肺过度充气是唯一与钙化评分(每呼气/吸气CT肺容积高0.2:OR 1.2,95%CI 1.1-1.5,P=0.02)、临床冠状动脉疾病(OR 1.6,95%CI 1.1-2.3,P=0.01)和心肌梗死(COPDGene中OR 1.7,95%CI 1.0-2.8,P=0.05)相关的表型。
- FEV1和肺气肿在调整冠状动脉疾病危险因素的模型中与冠状动脉疾病风险增加相关(P<0.05),但调整肺过度充气后关联减弱。
- 在气流阻塞者中结果相同,且两个队列中均存在该关联。
证据类型、等级与局限
- 证据类型:两个队列(SCCOR队列和COPDGene队列)的分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在吸烟者中评估冠状动脉疾病风险时,肺过度充气与临床和亚临床冠状动脉疾病强相关,调整肺过度充气后FEV1和肺气肿不再与冠状动脉疾病相关。
- 作者认为,后续研究应考虑测量肺过度充气并探讨其在现吸烟者和既往吸烟者冠状动脉疾病中的机制作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Smokers manifest varied phenotypes of pulmonary impairment.
RESEARCH QUESTION: Which pulmonary phenotypes are associated with coronary artery disease (CAD) in smokers?
STUDY DESIGN AND METHODS: We analyzed data from the University of Pittsburgh COPD Specialized Center for Clinically Oriented Research (SCCOR) cohort (n = 481) and the Genetic Epidemiology of COPD (COPDGene) cohort (n = 2,580). Participants were current and former smokers with > 10 pack-years of tobacco exposure. Data from the two cohorts were analyzed separately because of methodologic differences. Lung hyperinflation was assessed by plethysmography in the SCCOR cohort and by inspiratory and expiratory CT scan lung volumes in the COPDGene cohort. Subclinical CAD was assessed as the coronary artery calcium score, whereas clinical CAD was defined as a self-reported history of CAD or myocardial infarction (MI). Analyses were performed in all smokers and then repeated in those with airflow obstruction (FEV1 to FVC ratio, < 0.70).
RESULTS: Pulmonary phenotypes, including airflow limitation, emphysema, lung hyperinflation, diffusion capacity, and radiographic measures of airway remodeling, showed weak to moderate correlations (r < 0.7) with each other. In multivariate models adjusted for pulmonary phenotypes and CAD risk factors, lung hyperinflation was the only phenotype associated with calcium score, history of clinical CAD, or history of MI (per 0.2 higher expiratory and inspiratory CT scan lung volume; coronary calcium: OR, 1.2; 95% CI, 1.1-1.5; P = .02; clinical CAD: OR, 1.6; 95% CI, 1.1-2.3; P = .01; and MI in COPDGene: OR, 1.7; 95% CI, 1.0-2.8; P = .05). FEV1 and emphysema were associated with increased risk of CAD (P < .05) in models adjusted for CAD risk factors; however, these associations were attenuated on adjusting for lung hyperinflation. Results were the same in those with airflow obstruction and were present in both cohorts.
INTERPRETATION: Lung hyperinflation is associated strongly with clinical and subclinical CAD in smokers, including those with airflow obstruction. After lung hyperinflation was accounted for, FEV1 and emphysema no longer were associated with CAD. Subsequent studies should consider measuring lung hyperinflation and examining its mechanistic role in CAD in current and former smokers.
参考来源
- Chandra D, Gupta A, Kinney GL, et al. The Association Between Lung Hyperinflation and Coronary Artery Disease in Smokers. Chest. 2021. PMID: 33971144. doi:10.1016/j.chest.2021.04.066
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。